Your browser doesn't support javascript.
loading
Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control.
Yang, Feng; Zhang, Jennifer; Buettner, Alexander; Vosika, Eva; Sadek, Monica; Hao, Zhiqi; Reusch, Dietmar; Koenig, Maximiliane; Chan, Wayman; Bathke, Anja; Pallat, Hilary; Lundin, Victor; Kepert, Jochen Felix; Bulau, Patrick; Deperalta, Galahad; Yu, Christopher; Beardsley, Richard; Camilli, Tura; Harris, Reed; Stults, John.
  • Yang F; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Zhang J; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Buettner A; Pharma Technical Development Analytics, Roche Diagnostics GmbH, Penzberg, Germany.
  • Vosika E; Pharma Technical Development Analytics, Roche Diagnostics GmbH, Penzberg, Germany.
  • Sadek M; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Hao Z; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Reusch D; Pharma Technical Development Analytics, Roche Diagnostics GmbH, Penzberg, Germany.
  • Koenig M; Large Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Chan W; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Bathke A; Pharma Technical Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Pallat H; Pharma Quality & Compliance-Analytical Science, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Lundin V; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Kepert JF; Pharma Technical Development Analytics, Roche Diagnostics GmbH, Penzberg, Germany.
  • Bulau P; Pharma Technical Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Deperalta G; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Yu C; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Beardsley R; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Camilli T; Pharma Technical Regulatory, Genentech, A Member of the Roche Group, South San Francisco, CA, USA.
  • Harris R; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
  • Stults J; Pharma Technical Development, Genentech, A member of the Roche Group, South San Francisco, CA, USA.
MAbs ; 15(1): 2197668, 2023.
Article en En | MEDLINE | ID: mdl-37057828
ABSTRACT
The multi-attribute method (MAM), a liquid chromatography-mass spectrometry (LC-MS)-based peptide mapping method, has gained increased interest and applications in the biopharmaceutical industry. MAM can, in one method, provide targeted quantitation of multiple site-specific product quality attributes, as well as new peak detection. In this review, we focus on the scientific and regulatory considerations of using MAM in product quality attribute monitoring and quality control (QC) of therapeutic proteins. We highlight MAM implementation challenges and solutions with several case studies, and provide our perspective on the opportunities to use MS in QC for applications other than standard peptide mapping-based MAM.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Anticuerpos Monoclonales Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Anticuerpos Monoclonales Idioma: En Año: 2023 Tipo del documento: Article